Last reviewed · How we verify
MT-3995 High
At a glance
| Generic name | MT-3995 High |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy (PHASE2)
- Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy (PHASE2)
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR (PHASE2)
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria (PHASE2)
- Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-3995 High CI brief — competitive landscape report
- MT-3995 High updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI